Despite advances, the roles of genetics and microenvironment in CLL are not fully understood, and curative treatments may hinge on a dual approach targeting both.

A total of 545 subjects with episodic or chronic migraine, who are aged 18 and above, were included in the trial.

AbbVie’s migraine drug Atogepant just cleared a major Phase 3 hurdle, and it’s got Wall Street rubbing its temples—in ...

(Reuters) -AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment ...

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.

Shares of AbbVie (ABBV) were in the spotlight on Wednesday after the company announced positive results from a late-stage ...

AbbVie’s latest Phase 3 TEMPLE study delivers a real headache for migraines—and topiramate. The study found that patients ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a generic drug in a head-to head late-stage ...

Limiting pharma ads would be a major win for Health and Human Services Secretary Robert F. Kennedy Jr. He has long wanted to ...

Health and Human Services Secretary Robert F. Kennedy Jr. wants to make it harder and more expensive for drug companies to advertise to patients.

Two Democratic lawmakers have renewed accusations that large pharma companies have evaded paying U.S. taxes through a ...

This was the stock's third consecutive day of losses.